Trailhead Biosystems

Trailhead Biosystems, driven by our proprietary HD-DoE™ platform develops industrial grade human iPSC-derived cells much more quickly, at lower cost, and with less R&D risk than others in the industry. We merge developmental biology with cutting-edge robotics, mathematics, and computerized experimental design and analysis to perform process-specific parameter optimization. This allows us to rapidly develop de novo protocols for the development of any human cell type for use in drug discovery, drug safety, or for therapeutic purposes.